Industry Watch [to 9 April 2016]
:: Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13
Four-Dose Vial Will Help Address Infrastructure Challenges in Developing Countries

April 06, 2016 NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved a new four-dose, multi-dose vial (MDV) presentation of Prevenar 13®* (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). This new MDV presentation was developed to help maximize efficiency for health care workers by helping to significantly reduce storage requirements and shipping costs in communities with health systems that are still developing.

“With this new presentation, a box that once carried enough vaccine to help protect 50 infants and children will potentially vaccinate 200, helping to ensure Prevenar 13® is accessible in the most remote regions of the world where the greatest burden of invasive pneumococcal disease lies.”

The MDV presentation of Prevenar 13® offers significant benefits to developing countries, including a 75 percent reduction in:
:: Temperature-controlled supply chain requirements,
:: United Nations International Children’s Education Fund (UNICEF) shipping costs, and
:: Storage requirements at the national, regional, district, and community levels.

“Prevenar 13® is the first approved pneumococcal conjugate vaccine available in a preserved multi-dose vial presentation,” said Luis Jodar, Ph.D., global vice president, Vaccines, Pfizer Global Medicines Development Group and Medical/Scientific Affairs. “With this new presentation, a box that once carried enough vaccine to help protect 50 infants and children will potentially vaccinate 200, helping to ensure Prevenar 13® is accessible in the most remote regions of the world where the greatest burden of invasive pneumococcal disease lies.”…